ARTICLE | Clinical News
GD0039: Phase II
January 28, 2002 8:00 AM UTC
An open-label Canadian Phase II study of GD0039 given orally twice daily in 18 patients with metastatic renal cancer showed a median survival time of 17.2 months. GD said that 9 of the patients are st...